Logo

Somalogic Joins UK Dementias Research Platform

Jun 28, 2014
Premium

NEW YORK (GenomeWeb) – Somalogic said this week that it has joined the Medical Research Council's UK Dementias Research Platform.

The UKDP is a $27 million public-private partnership that aims to enable earlier detection and improved treatments for dementia. It brings together industry players and investigators from eight universities for research into neurodegenerative diseases including Alzheimer's, Parkinson's, and motor neuron disease.

In additional to Somalogic, the initiative is partnering with companies including MedImmune, GSK; and Janssen Research & Development.

Filed under

Proteomics & Protein Research
proteomics
Somalogic
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.